<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641873</url>
  </required_header>
  <id_info>
    <org_study_id>D8809001</org_study_id>
    <nct_id>NCT02641873</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I Study of BBI608 Administered With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI +
      Bavacizumab. This study population is adult Japanese patients with metastatic colorectal
      cancers in FOLFIRI + Bevacizumab combination therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability assessed by adverse events (AEs), serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability assessed by determination of unacceptable toxicity in patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Peak plasma concentration)</measure>
    <time_frame>Day 1: prior to BBI608 and 2,4,6,8,10,12,24 hours after the first dose.</time_frame>
    <description>Cmax (Peak plasma concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24h (Area under the plasma concentration versus time curve)</measure>
    <time_frame>Day 1: prior to BBI608 and 2,4,6,8,10,12,24 hours after the first dose.</time_frame>
    <description>AUC0-24h (Area under the plasma concentration versus time curve)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumour activity</measure>
    <time_frame>6 months(an expected average)</time_frame>
    <description>The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Participants follow-up for progression free survival will occur. Maximum follow-up time is 12 months after the initial administration of the last subject.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <description>240 mg twice daily (480 mg total daily dose)</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofolinate</intervention_name>
    <description>200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A histologically confirmed advanced unresectable, metastatic or recurrent colorectal
             carcinoma

          2. Evaluable patient by RECISTversion 1.1

          3. Stage IV

          4. ≥ 20 years of age

          5. Life expectancy ≥ 3 months.

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          7. Patients with following organ function within 14 days before enrollment (on the basis
             of the most recent data during the period if multiple data are available)

               -  Hemoglobin (Hg) ≥ 9.0 g/dL

               -  Neutrophil count ≥ 1.5 x 103/μL

               -  Platelet count ≥ 10 x 104/μL

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × institutional
                  upper limit of normal (ULN) [≤ 5 × ULN in presence of liver metastases ]

               -  Total bilirubin ≤ 1.5 × institutional ULN [≤ 2 × ULN in presence of liver
                  metastases ]

               -  Creatinine ≤ 1.5 × institutional ULN

               -  Proteinuria by dipstick urine analysis ≤ 1+. [ UPCR (Urine Albumin-to-Creatinine
                  Ratio) ≤ 1, or protein volume of 24-hour urine collection ≤ 1 g, in the case of
                  patients with a 2+ urine dipstick reading]

          8. For female patient of child producing potential: Must agree to use contraception or
             take measures to avoid pregnancy during the study and for 30 days after the last
             protocol treatment dose or 6 months after Bevacizumab treatment.. For male patient of
             child producing potential: Must agree to use contraception or take measures to avoid
             pregnancy during the study and for 90 days after the last protocol treatment dose or 6
             months after Bevacizumab treatment

          9. Females of childbearing potential have a negative urine pregnancy test

         10. Patients who have provided written voluntary consent in person to participate in this
             study after fully receiving and understanding the information about this study,
             including study

        Exclusion Criteria:

          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or hormone therapy, or heart
             therapy within 21 days of the first dose of BBI608

          2. Major surgery within 28 days prior to first dose

          3. Have had a brain metastases with a symptom or requiring treatment

          4. Have had coinstantaneously active multiple primary cancer

          5. Have had a carcinomatous pleural effusion, ascites, or cardiac effusion requiring
             treatment

          6. Crohn's disease, ulcerative colitis, small intestine resection, diarrhea (watery
             diarrhea), paralysis intestinal, Intestinal obstruction

          7. Gastrointestinal perforation, tracheo-oesophageal fistula, fistula

          8. Unable or unwilling to swallow BBI608 capsules

          9. Uncontrolled inter-current illness (such as Grade 3 active infection, or serious
             respiratory disease)

         10. Uncontrolled hypertension

         11. Patients with recent history of hemoptysis of more than 2.5 mL of red blood within
             28days before the enrolment

         12. Abnormal ECGs which are clinically significant within 28 days before enrolment

         13. Patients who are New York Heart Association (NYHA) functional classes III, or IV, or
             unstable angina

         14. Patients newly expressing angina within three months (90 days) before the enrolment

         15. Have had myocardial infarction within six months (180 days)before the enrolment

         16. Administrating with antiarrhythmic drug

         17. Patients who are planning to breast-feeding by whichever 30 days after the last
             administration of BBI608 or by 6 months after the last administration of Bevacizumab

         18. Patients of pregnancy or possibility of pregnancy at current time or possibility of
             pregnancy within 6 months after the last administration of Bevacizumab

         19. Have received other investigational products or not finished the assessment in any
             clinical study within 28 days before enrollment

         20. Known severe hypersensitivity to 5-FU/ levofolinate/ irinotecan/Bevacizumab

         21. Administration of atazanavir sulfate

         22. Prior treatment with BBI608

         23. Ineligible for participation in the study in the opinion of the Investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic Colorectal Cancer</keyword>
  <keyword>mCRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

